Find your next paid study

University of OklahomaNCT05512208

Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products

This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study…

MelanomaMetastatic MelanomaAdvanced Solid Tumor+1 more

Replimune, Inc.NCT06887348

~$10 – $1,050

Glioblastoma MultiformeAnaplastic AstrocytomaFibrillary Astrocytomas+5 more

Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab i…

University of MiamiNCT05956821

Observational

Evaluation of a Decision Aid in the Treatment Planning of Small Renal Tumors

The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for tre…

Kidney TumorRenal Cancer

NYU Langone HealthNCT05387863

~$10 – $7,500

A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effec…

Advanced Solid Tumors

Pikavation Therapeutics, Inc.NCT06736704

Observational

Navigation and Research: Evaluating the Intervention of Central Navigation and an Oncology Research Navigator (ORN) on Cancer Outcomes and Clinical Trial Enrollment (NAVIGATE Trial)

This health services interventional study investigates the effectiveness of central oncology navigation (SOC ) alone and central oncology navigation with a new…

CancerMalignant Tumor

UNC Lineberger Comprehensive Cancer CenterNCT06618274

PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and pre…

Relay Therapeutics, Inc.NCT05216432

UCSF Biobank for Studying Hereditary Cancers and Tumor-Associated Mutations

This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hered…

Solid TumorSolid Tumor, AdultSomatic Mutation+2 more

University of California, San FranciscoNCT06895681

~$10 – $675

A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

Solid Tumors

Quanta TherapeuticsNCT06227377

Advanced Refractory Solid TumorsSubjects Considered Likely to Respond to CB-03-10

Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors

Subjects will undergo baseline evaluation and an assessment of extent of disease. Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-…

Cosmo Technologies LtdNCT03863145

Phase 2

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients…

Brain MetastasesTumor

M.D. Anderson Cancer CenterNCT05064280

CancerTumor, SolidMalignant Neoplasm+4 more

A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokineti…